Category: Technology Licenses
Created On: 2022-04-28
Record Count: 11
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 87659
Subject to the Right of First Refusal and Option below, Licensor shall not license to any third party, and hereby grants an exclusive option to Licensee to license, the Licensor IP Rights to develop, make, have made, use, sell, offer to sell, import and export (or otherwise commercialize and exploit) naloxone for treatment or prevention of opioid overdose in the Territory.
Compound Naloxone or Option Compound and any metabolite, salt, ester, hydrate, anhydride, solvate, isomer, enantiomer, free acid form, free base form, crystalline form, co-crystalline form, complexes, amorphous form, pro-drug (including ester pro-drug) form, racemate, polymorph, chelate, isomer, tautomer, or optically active form of the foregoing.
Option Compound Naltrexone and nalmephene/ nalmefene.
Naloxone is a medication used to block the effects of opioids, especially in overdose. Naloxone may be combined within the same pill as an opioid to decrease the risk of misuse.
Naloxone blocks or reverses the effects of opioid medication, including extreme drowsiness, slowed breathing, or loss of consciousness. An opioid is sometimes called a narcotic.
Naloxone is used to treat a narcotic overdose in an emergency situation. This medicine should not be used in place of emergency medical care for an overdose.
Naloxone is also used to help diagnose whether a person has used an overdose of an opioid.
IPSCIO Record ID: 256780
4,883,867 – Detection of reticulocytes, RNA or DNA
6,355,631 – Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation
7,652,154 – Method and intermediates for the preparation of derivatives of N (1-benzhydrylazetidin-3-yl)-N-phenylmethylsulfonamide
Licensed Compound means the pharmaceutical compound known as AVE1625 (drinabant), as more specifically described, together with any metabolite, salt, ester, hydrate, solvate, isomer, enantiomer, free acid form, free base form, crystalline form, co-crystalline form, amorphous form, pro-drug form, racemate, polymorph, chelate, stereoisomer, tautomer or optically active form of any of the foregoing.
IPSCIO Record ID: 189493
Product means any pharmaceutical product or medical device, whether prescription or over-the-counter, marketed for a treatment of opioid overdose containing naloxone, alone or in combination with one or more other active or inactive ingredients, in any intranasal form, presentation, strength or delivery systems; provided, however, that Product shall not refer to any product Controlled, developed, manufactured, marketed, sold, offered for sale, exported, or imported directly or indirectly by a Sublicensee if such Sublicenseeâ€™s rights in respect of such product were obtained or developed independently of any sublicense or right granted by Licensee hereunder.
Product Specific Patents
US Application No. 61/953,379 Filing Date 3/14/2014 – NASAL DRUG PRODUCTS AND METHODS OF THEIR USE
US Application No. 62/022,268 Filing Date 7/9/2014 – CO-PACKAGED DRUG PRODUCTS
IPSCIO Record ID: 344646
English Licensor hereby grants to Licensee (and its Affiliates and Sublicensees) access to, and a right of reference with respect to, any Regulatory Materials, to the extent Controlled by Licensor at the Commencement Date, for the purposes of Exploiting the Licensor Licensed Compound and Licensed Products in the Field in the Territory. Licensor agrees to execute, acknowledge, and deliver any further documents or instruments and to perform all such other acts as may be reasonably necessary or appropriate in order to effect such right of reference.
Licensed Product means any pharmaceutical product containing a Licensor Licensed Compound in any and all forms, presentations, delivery systems, dosages, and formulations.
V24343 means the molecule and structure and any metabolite, salt, ester, hydrate, solvate, isomer, enantiomer, free acid form, pro-drug (including ester pro-drug) form, racemate, polymorph, chelate, stereoisomer, tautomer, resinate or optically active form thereof.
Licensor Licensed IP means any and all Licensor Know How including the Licensor Regulatory Materials and Licensor Licensed Compound Information.
IPSCIO Record ID: 359061
With respect to the applicable Reversion Compounds being terminated, Licensor grants, effective upon such termination, an exclusive even us to Licensor. sub-licensable, worldwide license under the Licensor Reversion Technology to research, develop, import, use, make. have made, offer for sale and sell Reversion Compounds and Reversion Products including as part of a Licensee Combination Therapy in the Field in the Territory.
Reversion Compound means NLG919, any Next Generation Compound or any Subsequent Compound.
NLG919 means Licenseeâ€™s proprietary small molecule IDO inhibitor known as of the Execution Date as NLG919, or any enantiomer, polymorph, salt form, base, acid, racemate, isomer, diastereomer, tautomer, solvate, hydrate, ester or Known Prodrug thereof.
Next Generation Compound means any Compound other than NLG919 that is invented, by or on behalf of Licensee or its Affiliate, whether solely or jointly, as of the Effective Date or thereafter during the Restriction Period, whether or not pursuant to the Research Plan, that is invented or otherwise the subject of research or preclinical development conducted, by or on behalf of Licensor or its Affiliate or Sublicensee, but excluding the pRED Organization, whether solely or jointly, during the Next Gen Research Term, whether or not pursuant to the Research Plan, the composition of matter, manufacture or use of which is Covered by a Valid Claim of a Licensee Patent or Collaboration Patent; or that is an enantiomer, polymorph, salt form, base, acid, racemate, isomer, diastereomer, tautomer, solvate, hydrate, ester or Known Prodrug of a Compound described above.
Indication means any separately defined. well-categorized class of human disease, syndrome or medical condition for which a separate MAA may be filed with a Regulatory Authority. Each different tumor type or a different hematological malignancy as classified by cell lineage (e.g., acute lymphoblastic leukemia is a different Indication from chronic myclogenous leukemia) shall be a separate Indication; however each different line of therapy for a particular tumor type or hematological malignancy will not he considered a separate Indication.
IPSCIO Record ID: 273379
Licensor grants a worldwide, non-exclusive license to the Licensor Trademark, solely for the purpose of fulfilling Licensees obligations in relation to this Agreement.
Other Compound means diazepam (7-chloro-l-methyl-5-phenyl-l ,3-dihydro-2H-1 ,4- benzodiazepin-2-one). including all salts, esters, complexes, chelates, hydrates, isomers, stereoisomers, crystalline forms, amorphous forms, prodrugs (including all compounds that are metabolized or dissolve into the same active moiety in the body), solvates, metabolites/metabolic precursors, and pegylated form thereof.
Product means the nasal formulation of Product Intermediate incorporated or filled into a Device.
Buccal Formulation means formulations of Product Intermediate for administration by placing in the mouth for absorption through the cheek, the gum or the upper or lower inside lip without swallowing, achieved by means of a muco adhesive, including but not limited to any specific formulation that may be selected for commercialization.
Field means the use as a prescription or over-the-counter pharmaceutical product in humans, specifically excluding diagnostic use.
Licensee acquired global rights to a novel nasal lorazepam formulation for the treatment of emergency seizures in epilepsy patients.
IPSCIO Record ID: 279342
Licensor Patent Rights are identified as
4,719,215 – Quaternary derivatives of noroxymorphone which relieve nausea and emesis
4,861,781 – Quaternary derivatives of noroxymorphone which relieve nausea and emesis
5,102,887 – Method for reducing emesis and nausea induced by the administration of an emesis causing agent
To relieve pain, narcotic medications such as morphine activate specific opioid receptors located in the central nervous system – the brain and spinal cord. Opioids, however, also interact with these receptors outside of the central nervous system, resulting in side effects, which can be debilitating, including constipation, urinary retention and severe itching. MNTX is designed to block peripheral opioid receptors whose activation causes these side effects. As MNTX does not cross the blood-brain barrier, it does not interfere with brain-centered pain relief.
IPSCIO Record ID: 221363
(a) to Commercialize the Product in the Territory;
(b) to Manufacture in any country the quantities of Product required for Commercialization in the Territory; and
(c) to Develop the Product for Commercialization in the Territory.
â€œAPIâ€ means the active pharmaceutical ingredient macimorelin acetate, and any metabolite, salt, ester, hydrate, solvate, isomer, enantiomer, free acid form, free base form, crystalline form, co-crystalline form, amorphous form, pro-drug, racemate, polymorph, chelate, stereoisomer, tautomer, or optically active form of any of the foregoing.
Macrilenâ„¢ (macimorelin) is an orally-active ghrelin agonist that stimulates the secretion of growth hormone. Macrilenâ„¢ (macimorelin) has been granted orphan drug designation by the FDA for the evaluation of growth hormone deficiency. On December 20, 2017, the FDA granted Licensor marketing approval for Macrilenâ„¢ (macimorelin) to be used in the diagnosis of patients with adult growth hormone deficiency (â€œAGHDâ€).
â€œAdult Indicationâ€ means assessing GHD in adults.
â€œGHDâ€ means growth hormone deficiency.
AGHD reportedly affects approximately 60,000 adults across the U.S. and Canada. Growth hormone not only plays an important role in growth from childhood to adulthood, but also helps promote a hormonally-balanced health status. AGHD mostly results from damage to the pituitary gland. It is usually characterized by a reduction in bone mineral density, lean body mass, exercise capacity, and overall quality of life as well as an increase of cardiovascular risks.
Licensor Trademarkâ€ means the Macrilen trademark registered in the Territory and any accompanying logos, trade names, trade dress and/or other indicia relating to the Product Controlled by the Licensor.
IPSCIO Record ID: 372413
Crohn's disease is a type of inflammatory bowel disease (IBD) that may affect any segment of the gastrointestinal tract from the mouth to the anus
IPSCIO Record ID: 324330
The German Licensor grants to the Licensee of Ireland a joint ownership interest in the Licensor Patent Rights and Trademarks (Joint Ownership Interest) and a non-assignable right and license to use the Licensor IPR Package (Licensors know-how and Intellectual Property rights)
to Commercialize the Product in the Territory;
to Manufacture in any country the quantities of Product required for Commercialization in the Territory; and
to Develop the Product for Commercialization in the Territory.
With this amendment, Licensee now has a joint ownership interest under the Licensor Patent Rights and the Licensor Trademarks to carry out development, manufacturing, registration and commercialization of the Product in the Territory.
Patents are or relate to Growth Hormone Secretagogues; Methods and kits to diagnose Growth Hormone Deficiency; Method of Assessing Growth Hormone Deficiency Comprising Oral Administration of a Macimorelin Containing Composition and Collecting One or Two Post-administration Samples; Use of Macimorelin in Assessing Growth Hormone Deficiency in Children; A novel peptide-mimetic GH secretagogue with potent and selective GH-releasing activity in man by Broglio et al; Targeting the Ghrelin Receptor; and, GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults.
API means the active pharmaceutical ingredient macimorelin acetate, and any metabolite, salt, ester, hydrate, solvate, isomer, enantiomer, free acid form, free base form, crystalline form, co-crystalline form, amorphous form, pro-drug, racemate, polymorph, chelate, stereoisomer, tautomer, or optically active form of any of the foregoing.
Trademark means the Macrilen trademark registered in the Territory and any accompanying logos, trade names, trade dress and/or other indicia relating to the Product Controlled by Licensor.
Macimorelin (INN), or Macrilen (trade name) is a drug being developed for use in the diagnosis of adult growth hormone deficiency.
IPSCIO Record ID: 233451
The initial compound means the compound ICA-17043 having the molecular structure set forth and any hydrates, anhydrides, solvates, salts, esters, isomers, prodrugs, metabolites or polymorphs thereof.
The Product means a pharmaceutical product that contains, incorporates or is comprised of the Compound, whether in development or approved by any Regulatory Authority, including all formulations, line extensions and modes of administration thereof.
The Licensor Patents means all Patents, other than CMCC Patents, Controlled by Licensor as of the Effective Date or during the Term, that, absent rights thereunder, would be infringed by the Development, Manufacture, formulation, use, distribution, importation, sale, or offer for sale of Compound or Product, including without limitation any such Patents claiming the composition of matter or the use of Compound or Product or any Improvements thereto.
Licensors know-how means all Information, except for CMCC Know-How, that Licensor Controls as of the Effective Date or during the Term.